Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $4.92 Consensus PT from Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have been given a consensus recommendation of “Hold” by the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.9167.

Several brokerages recently issued reports on VVOS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. HC Wainwright started coverage on shares of Vivos Therapeutics in a report on Monday, November 17th. They set a “buy” rating and a $7.00 target price for the company. Zacks Research upgraded Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 1st. Finally, Ascendiant Capital Markets reduced their price objective on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating for the company in a research report on Wednesday, December 3rd.

Vivos Therapeutics Price Performance

Shares of NASDAQ:VVOS opened at $1.62 on Friday. The firm has a market capitalization of $15.29 million, a P/E ratio of -0.92 and a beta of 6.89. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.78 and a current ratio of 0.78. The stock has a 50 day moving average price of $2.04 and a 200-day moving average price of $3.07. Vivos Therapeutics has a 52-week low of $1.56 and a 52-week high of $7.95.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. The company had revenue of $6.78 million for the quarter, compared to analyst estimates of $4.49 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%. As a group, equities research analysts anticipate that Vivos Therapeutics will post -1.79 EPS for the current fiscal year.

Institutional Trading of Vivos Therapeutics

Several institutional investors have recently bought and sold shares of the company. Connective Capital Management LLC purchased a new position in Vivos Therapeutics in the third quarter worth about $620,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics in the 2nd quarter worth approximately $220,000. Finally, XTX Topco Ltd purchased a new position in Vivos Therapeutics in the 2nd quarter worth approximately $65,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.